The DOI matches its Crossref record.
A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia–reperfusion injury
Open accessAbstract
The cytokine erythropoietin (EPO) protects the heart from ischemic injury, in part by preventing apoptosis. However, EPO administration can also raise the hemoglobin concentration, which, by increasing oxygen delivery, confounds assignment of cause and effect. The availability of EPO analogs that do not bind to the dimeric EPO receptor and lack erythropoietic activity, e.g., carbamylated EPO (CEPO), provides an opportunity to determine whether EPO possesses direct cardioprotective activity. In vivo , cardiomyocyte loss after experimental myocardial infarction (MI) of rats (40 min of occlusion with reperfusion) was reduced from ≈57% in MI-control to ≈45% in animals that were administered CEPO daily for 1 week (50 μg/kg of body weight s.c.) with the first dose administered intravenously 5 min before reperfusion. CEPO did not increase the hematocrit, yet it prevented increases in left ventricular (LV) end-diastolic pressure, reduced LV wall stress in systole and diastole, and improved LV response to dobutamine infusion compared with vehicle-treated animals. In agreement with the cardioprotective effect observed in vivo , staurosporine-induced apoptosis of adult rat or mouse cardiomyocytes in vitro was also significantly attenuated (≈35%) by CEPO, which is comparable with the effect of EPO. These data indicate that prevention of cardiomyocyte apoptosis, in the absence of an increase in hemoglobin concentration, explains EPO's cardioprotection. Nonerythropoietic derivatives such as CEPO, devoid of the undesirable effects of EPO, e.g., thrombogenesis, could represent safer and more effective alternatives for treatment of cardiovascular diseases, such as MI and heart failure. Furthermore, these findings expand the activity spectrum of CEPO to tissues outside the nervous system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
Vollmar, B., & Menger, M. D. (2009) · Physiological Reviews · doi:10.1152/physrev.00027.2008 · Cited by 500
Anemia in Chronic Heart Failure: Prevalence, Etiology, Clinical Correlates, and Treatment Options
Tang, Y.-D., & Katz, S. D. (2006) · Circulation · doi:10.1161/circulationaha.105.583666 · Cited by 415
Systems approaches to preventing transplanted cell death in cardiac repair
Robey, T. E., Saiget, M. K., Reinecke, H., & Murry, C. E. (2008) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2008.03.009 · Cited by 404
The non‐haematopoietic biological effects of erythropoietin
Arcasoy, M. O. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07014.x · Cited by 347
Metadata
- Authors
- Fiordaliso, F., Chimenti, S., Staszewsky, L., Bai, A., Carlo, E., Cuccovillo, I., Doni, M., Mengozzi, M., Tonelli, R., Ghezzi, P., Coleman, T., Brines, M., Cerami, A., & Latini, R.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2005-01-25
- Volume
- 102
- Issue
- 6
- Pages
- 2046-2051
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2068624628
- Cited by
- 223
- References
- 0
- FWCI
- 16.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia–reperfusion injury. https://app.cochat.ai/papers/10.1073/pnas.0409329102
- The paper
- Fiordaliso, F., Chimenti, S., Staszewsky, L., Bai, A., Carlo, E., Cuccovillo, I., Doni, M., Mengozzi, M., Tonelli, R., Ghezzi, P., Coleman, T., Brines, M., Cerami, A., & Latini, R. (2005). A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia–reperfusion injury. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0409329102
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.